Synfacts 2021; 17(09): 0961
DOI: 10.1055/s-0040-1720754
Synthesis of Natural Products and Potential Drugs

Synthesis of PF-06873600

Contributor(s):
Philip Kocienski
Freeman-Cook KD. * et al. Pfizer Global Research & Development, La Jolla, USA
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.

J. Med. Chem. 2021;
64: 9056-9077
DOI: 10.1021/acs.jmedchem.1c00159.
 

Significance

The cyclin-dependent kinases (CDKs) are a 21-member family of serine-threonine kinases that are involved in a diverse array of cellular processes. PF-06873600 is a selective cyclin-­dependent kinase 2/4/6 inhibitor that advanced to phase I clinical trials in 2018 for the treatment of cancer. The highly efficient (1R,2R)-2-hydroxy-2-methycyclopentyl-1-amine moiety [(1R,2R)-B (US 2018 0044344 A1)] provided a marked improvement in lipophilicity with consequent better potency and metabolic stability.


#

Comment

A key step in the synthesis of PF-06873600 is a C–H functionalization reaction by which a difluoromethyl radical is generated from a sulfinate precursor (I) and tert-butyl hydroperoxide in the presence of iron or other inorganic counter-ions (Y. Fujiwara J. Am. Chem. Soc. 2012, 134, 1494; F. O’Hara et al. J. Am. Chem. Soc. 2013, 135, 12122). In this system, the resultant difluoromethyl radical reacts regioselectively at the 6-position of the pyridopyrimidinone core and provides the target molecule in 57% yield.


#
#

Publication History

Article published online:
18 August 2021

© 2021. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany